Muscarinic M3 receptor and beta-2 adrenergic receptor — Drug Target

All drugs that target Muscarinic M3 receptor and beta-2 adrenergic receptor — marketed and clinical-stage. Includes 3 drug classes acting on this target.

Drug classes

Long-acting muscarinic antagonist / long-acting beta-2 agonist combination (LAMA/LABA) · Long-acting anticholinergic/long-acting beta-2 agonist combination (LAMA/LABA) · LAMA/LABA combination bronchodilator

Marketed (2)

• TIO/OLO · GlaxoSmithKline · Long-acting muscarinic antagonist / long-acting beta-2 agonist combination (LAMA/LABA) · Respiratory / Pulmonology
  TIO/OLO is a fixed-dose combination of tiotropium (a long-acting muscarinic antagonist) and olodaterol (a long-acting beta-2 agonist) that works synergistically to relax and open airways in chronic obstructive pulmonary disease.
• Aclidinium bromide/formoterol fumarate combination · AstraZeneca · Long-acting anticholinergic/long-acting beta-2 agonist combination (LAMA/LABA) · Respiratory/Pulmonology
  Aclidinium bromide and formoterol fumarate work together as a long-acting anticholinergic and long-acting beta-2 agonist to relax airway smooth muscle and improve airflow in chronic obstructive pulmonary disease.

Phase 3 pipeline (1)

• LAMA/LABA · Queen's University · LAMA/LABA combination bronchodilator · Respiratory/Pulmonology
  LAMA/LABA is a dual bronchodilator combining a long-acting muscarinic antagonist and long-acting beta-2 agonist to relax airway smooth muscle and improve airflow.